Creating artificial lymphoid tissues to study immunity and hematological malignancies

Current Opinion in Hematology
Shivem B Shah, Ankur Singh


The specialized microenvironments of lymphoid tissue affect immune cell function and progression of disease. However, current animal models are low throughput and a large number of human diseases are difficult to model in animals. Animal models are less amenable to manipulation of tissue niche components, signalling pathways, epigenetics, and genome editing than ex vivo models. On the other hand, conventional 2D cultures lack the physiological relevance to study precise microenvironmental interactions. Thus, artificial tissues are being developed to study these interactions in the context of immune development, function, and disease. New bone marrow and lymph node models have been created to, respectively, study microenvironmental interactions in hematopoiesis and germinal center-like biology. These models have also been extended to understand the effect of these interactions on the progression and therapeutic response in leukemia, multiple myeloma, and lymphoma. 3D in-vitro immune models have elucidated new cellular, biochemical, and biophysical interactions as potential regulatory mechanisms, therapeutic targets, or biomarkers that previously could not be studied in animal models and conventional 2D cultures. Incorporation of...Continue Reading


May 16, 2000·Leukemia & Lymphoma·J S Damiano, W S Dalton
Aug 8, 2001·Advanced Drug Delivery Reviews·M A Swartz
Aug 29, 2007·Immunity·Christopher D C AllenJason G Cyster
Oct 17, 2007·Journal of Biomedical Materials Research. Part a·Agnieszka N Stachowiak, Darrell J Irvine
Aug 13, 2010·Nature·Simón Méndez-FerrerPaul S Frenette
Oct 19, 2010·Biomaterials·Nunzia Di MaggioIvan Martin
Jun 15, 2011·Expert Review of Hematology·Edward Allan R Sison, Patrick Brown
Sep 13, 2011·Biomaterials·Teresa Mortera-BlancoNicki Panoskaltsis
Jul 18, 2012·Biomaterials·Mónica S Ventura FerreiraSabine Neurs
Sep 3, 2013·Advanced Healthcare Materials·Bhushan P MahadikBrendan A C Harley
May 6, 2014·Nature Methods·Yu-suke TorisawaDonald E Ingber
Jun 16, 2015·Biomaterials·Alberto PurwadaAnkur Singh
Sep 12, 2015·Biotechnology Journal·Ji Sun ChoiBrendan A C Harley
Mar 20, 2016·Tissue Engineering. Part C, Methods·Yu-Suke TorisawaDonald Ingber
Dec 23, 2016·Scientific Reports·Rami El AssalUtkan Demirci
Dec 31, 2016·Proceedings of the National Academy of Sciences of the United States of America·Francois BordeleauCynthia A Reinhart-King
Feb 13, 2017·ACS Biomaterials Science & Engineering·Alberto PurwadaAnkur Singh

❮ Previous
Next ❯


Jan 4, 2019·Advanced Healthcare Materials·Wujin SunAli Khademhosseini
Jun 8, 2019·SLAS Technology·Mosfera A ChowduryEdmond W K Young
Feb 29, 2020·Tissue Engineering. Part B, Reviews·Ishani D PremaratneJason A Spector
Oct 20, 2020·Small Methods·Sushila MaharjanYu Shrike Zhang
Jan 5, 2021·Frontiers in Oncology·Cristina Scielzo, Paolo Ghia
Dec 28, 2019·Biomaterials·Daniel Naveed TavakolThomas Braschler
May 21, 2021·Frontiers in Immunology·Francesca Vittoria SbranaCristina Scielzo

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.